IRIS PubliCatt

Pane, Marika
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 4.590
NA - Nord America 4.190
AS - Asia 1.757
AF - Africa 35
SA - Sud America 35
OC - Oceania 7
Continente sconosciuto - Info sul continente non disponibili 4
Totale 10.618
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.133
DE - Germania 1.301
IT - Italia 1.068
SE - Svezia 744
SG - Singapore 686
CN - Cina 539
IE - Irlanda 365
ID - Indonesia 236
FR - Francia 221
UA - Ucraina 194
GB - Regno Unito 181
RU - Federazione Russa 164
FI - Finlandia 97
IN - India 97
TR - Turchia 48
BE - Belgio 41
CA - Canada 39
HK - Hong Kong 37
IR - Iran 35
NL - Olanda 33
CZ - Repubblica Ceca 28
ES - Italia 27
JP - Giappone 23
CH - Svizzera 22
CI - Costa d'Avorio 22
BR - Brasile 19
PL - Polonia 15
KR - Corea 14
RO - Romania 13
RS - Serbia 13
MK - Macedonia 12
PA - Panama 12
IL - Israele 10
AR - Argentina 9
EG - Egitto 9
LT - Lituania 9
AT - Austria 8
HU - Ungheria 5
MX - Messico 5
PT - Portogallo 5
AU - Australia 4
DK - Danimarca 4
HR - Croazia 4
PH - Filippine 4
SK - Slovacchia (Repubblica Slovacca) 4
TW - Taiwan 4
A2 - ???statistics.table.value.countryCode.A2??? 3
AE - Emirati Arabi Uniti 3
CL - Cile 3
CO - Colombia 3
NZ - Nuova Zelanda 3
TH - Thailandia 3
BD - Bangladesh 2
BG - Bulgaria 2
BT - Bhutan 2
EE - Estonia 2
GR - Grecia 2
KZ - Kazakistan 2
LK - Sri Lanka 2
LV - Lettonia 2
MA - Marocco 2
PK - Pakistan 2
SA - Arabia Saudita 2
VN - Vietnam 2
ZA - Sudafrica 2
AL - Albania 1
AM - Armenia 1
GL - Groenlandia 1
ME - Montenegro 1
MT - Malta 1
MY - Malesia 1
NO - Norvegia 1
NP - Nepal 1
PY - Paraguay 1
QA - Qatar 1
XK - ???statistics.table.value.countryCode.XK??? 1
Totale 10.618
Salva come PNG Salva come JPEG
Città #
Chandler 993
Singapore 544
Ashburn 452
Dublin 331
New York 254
Jakarta 236
Rome 196
Milan 174
San Mateo 150
Jacksonville 117
Moscow 117
Marseille 104
Nanjing 99
Wilmington 93
Nürnberg 91
Boston 88
Princeton 78
Dearborn 77
Ann Arbor 70
Munich 67
Woodbridge 66
Houston 58
Beijing 50
Bremen 48
Los Angeles 48
Seattle 45
Helsinki 44
Fairfield 43
Nanchang 41
Brussels 35
Chicago 33
Redwood City 33
Lawrence 31
Palermo 30
Boardman 29
London 29
Hebei 27
Hong Kong 27
Lancaster 26
Pune 25
Brno 24
Cattolica 24
Detroit 24
Shanghai 24
Augusta 23
Toronto 23
Abidjan 22
Izmir 21
Kish 21
Norwalk 21
Jiaxing 20
Jinan 20
Paris 20
Leawood 18
Changsha 17
Redmond 17
Shenyang 17
Turin 17
University Park 17
Washington 16
Bologna 14
Busto Arsizio 14
Tianjin 14
Andover 13
Florence 13
Inverigo 13
Fremont 12
São Paulo 12
Cambridge 11
Guangzhou 11
Kunming 11
Naples 11
Ningbo 11
Santa Clara 11
Seoul 11
Zhengzhou 11
Lappeenranta 10
Menlo Park 10
Mountain View 10
Salamanca 10
Skopje 10
Bari 9
Hangzhou 9
Ottawa 9
Zurich 9
Madrid 8
Monza 8
Naaldwijk 8
Nuremberg 8
San Francisco 8
Taizhou 8
Tokyo 8
Edinburgh 7
Frankfurt am Main 7
Genoa 7
Vienna 7
Amsterdam 6
Cairo 6
Cinisello Balsamo 6
Krakow 6
Totale 5.892
Salva come PNG Salva come JPEG
Nome #
Reliability of the Performance of Upper Limb assessment in Duchenne muscular dystrophy 257
Oral and Swallowing Abilities Tool (OrSAT) for Type 1 SMA Patients: Development of a New Module 217
Cortical visual function in preterm infants in the first year. 210
Neurological examination of preterm infants a term equivalent age 187
Neurological examination at 6 to 9 months in infants with cystic periventricular leukomalacia 166
Crossed cerebellar atrophy of prenatal onset 157
Prognostic value of EEG performed at term age in preterm infants. 156
-Thalamic atrophy in infants with PVL and cerebral visual impairment 140
Performance of Upper Limb module for Duchenne muscular dystrophy 138
Visual development in prenatal post-haemorragic ventricular dilatation 129
Salbutamol increases survival motor neuron (SMN) transcript levels in leucocytes of spinal muscular atrophy (SMA) patients: relevance for clinical trial design. 126
Cardiac Function in Types II and III Spinal Muscular Atrophy: Should We Change Standards of Care? 126
Attention Deficit Hyperactivity Disorder and Cognitive Function in Duchenne Muscular Dystrophy: Phenotype-Genotype Correlation 121
SMN transcript levels in leukocytes of SMA patients determined by absolute real-time PCR. 120
Muscle MRI in Becker muscular dystrophy 118
Oral and Swallowing Abilities Tool (OrSAT) in nusinersen treated patients 110
A current approach to heart failure in Duchenne muscular dystrophy 107
Muscle MRI in Becker muscular dystrophy 103
Salbutamol increases serviva motor neuron (SMN) patients: relevance for clinical trial design 102
Congenital muscular dystrophies with cognitive impairment. A population study 102
Muscle MRI: Out of the tunnel. 101
Congenital muscular dystrophies with defective glycosylation of dystroglycan: a population study 100
Cardiac Function in Types II and III Spinal Muscular Atrophy: Should We Change Standars of Care? 100
Muscle magnetic resonance imaging involvement in muscular dystrophies with rigidity of the spine 98
Revised upper limb module for spinal muscular atrophy: Development of a new module 98
Functional changes in Duchenne muscular dystrophy: a 12-month longitudinal cohort study 96
Importance of SPP1 genotype as a covariate in clinical trials in Duchenne muscular dystrophy 96
A critical review of functional assessment tools for upper limbs in Duchenne muscular dystrophy 94
Genetic characterization in symptomatic female DMD carriers: lack of relationship between X-inactivation, transcriptional DMD allele balancing and phenotype 92
24 month longitudinal data in ambulant boys with duchenne muscular dystrophy 91
Expanded access program with Nusinersen in SMA type I in Italy: Strengths and pitfalls of a successful experience 90
Prevalence of Spinal Muscular Atrophy in the Era of Disease-Modifying Therapies: An Italian Nationwide Survey 88
Predominant distal muscle involvement in spinal muscular atrophy 87
MRI: Out of the tunnel. 85
-Electroclinical patterns and evolution of epilepsy in the 4p- syndrome 82
Respiratory Needs in Patients with Type 1 Spinal Muscular Atrophy Treated with Nusinersen 79
Developmental milestones in type I spinal muscular atrophy 79
Neurological assessment of newborns with spinal muscular atrophy identified through neonatal screening 78
Timed Rise from Floor as a Predictor of Disease Progression in Duchenne Muscular Dystrophy: An Observational Study 76
Upper limb function in Duchenne muscular dystrophy: 24 month longitudinal data. 76
Contactless: a new personalised telehealth model in chronic pediatric diseases and disability during the COVID-19 era 76
A 5-center experience with intrathecal administration of nusinersen in SMA1 in Italy letter to the editor of european journal of pediatric neurology regarding the manuscript "single-center experience with intrathecal administration of nusinersen in children with spinal muscular atrophy type 1" written by pechmann and colleagues". 74
Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy type 1 (STR1VE-EU): an open-label, single-arm, multicentre, phase 3 trial 74
Longitudinal evaluation of SMN levels as biomarker for spinal muscular atrophy: results of a phase IIb double-blind study of salbutamol 73
Histological effects of givinostat in boys with Duchenne muscular dystrophy 72
6 minute walk test in duchenne MD patients with different mutations:12 month changes 70
Different trajectories in upper limb and gross motor function in spinal muscular atrophy 70
Expanding the clinical-pathological and genetic spectrum of RYR1-related congenital myopathies with cores and minicores: an Italian population study 70
Developmental milestones in type I spinal muscular atrophy 69
Functional levels and MRI patterns of muscle involvement in upper limbs in Duchenne muscular dystrophy. 69
Clinical phenotypes and trajectories of disease progression in type 1 spinal muscular atrophy 69
Nusinersen in type 1 spinal muscular atrophy: Twelve-month real-world data 69
SMA-miRs (MiR-181a- 5p, -324-5p, and -451a) are overexpressed in spinal muscular atrophy skeletal muscle and serum samples 69
Experience of a 2-year spinal muscular atrophy NBS pilot study in Italy: towards specific guidelines and standard operating procedures for the molecular diagnosis 68
Patterns of disease progression in type 2 and 3 SMA: Implications for clinical trials 68
Health-related quality of life and functional changes in DMD: A 12-month longitudinal cohort study 68
The Spinal Muscular Atrophy Health Index: Italian validation of a disease-specific outcome measure 68
Does albuterol have an effect on neuromuscular junction dysfunction in spinal muscular atrophy? 67
An observational study of functional abilities in infants, children, and adults with type 1 SMA. 66
Revised north star ambulatory assessment for young boys with Duchenne muscular dystrophy 65
Longitudinal assessments in discordant twins with SMA 65
Age related treatment effect in type II Spinal Muscular Atrophy pediatric patients treated with nusinersen 64
SEPN1-related myopathies: clinical course in a large cohort of patients 63
6MWT can identify type 3 SMA patients with neuromuscular junction dysfunction 63
Assessing floppy infants: a new module 63
Type I SMA “new natural history”: long-term data in nusinersen-treated patients 61
SMA-miRs (MiR-181a- 5p, -324-5p, and -451a) are overexpressed in spinal muscular atrophy skeletal muscle and serum samples 61
Longitudinal natural history in young boys with Duchenne muscular dystrophy 60
Nusinersen efficacy data for 24-month in type 2 and 3 spinal muscular atrophy 60
Onasemnogene abeparvovec in spinal muscular atrophy: predictors of efficacy and safety in naïve patients with spinal muscular atrophy and following switch from other therapies 59
Implicit learning deficit in children with Duchenne muscular dystrophy: Evidence for a cerebellar cognitive impairment? 59
Early Gross Motor Milestones in Duchenne Muscular Dystrophy 59
Registries versus tertiary care centers: How do we measure standards of care in Duchenne muscular dystrophy? 58
New Mutations in NEB Gene Discovered by Targeted Next-Generation Sequencing in Nemaline Myopathy Italian Patients 58
Co-occurrence of fragile x syndrome with a second genetic condition: Three independent cases of double diagnosis 58
Pediatric Motor Inflammatory Neuropathy: The Role of Antiphospholipid Antibodies. 57
Sometimes they come back: New and old spinal muscular atrophy adults in the era of nusinersen 57
Ambulatory function in spinal muscular atrophy: Age-related patterns of progression. 55
Nusinersen in type 0 spinal muscular atrophy: should we treat? 55
Body mass index in type 2 spinal muscular atrophy: a longitudinal study 54
Nusinersen in pediatric and adult patients with type III spinal muscular atrophy 54
Validation and cross-cultural adaptation of the Italian version of the Pediatric Eating Assessment Tool (I-PEDI-EAT-10) in genetic syndromes 53
Co-occurrence of fragile x syndrome with a second genetic condition: Three independent cases of double diagnosis 53
Body mass index in type 2 spinal muscular atrophy: a longitudinal study 53
Revised upper limb module in type II and III spinal muscular atrophy: 24-month changes 53
Risdiplam-Treated Infants with Type 1 Spinal Muscular Atrophy versus Historical Controls 52
Muscle magnetic resonance imaging in congenital myopathies due to ryanodine receptor type 1 gene mutations 52
Long-term progression in type II spinal muscular atrophy: A retrospective observational study 52
The nonsense mutation stop+4 model correlates with motor changes in Duchenne muscular dystrophy 52
Age, corticosteroid treatment and site of mutations affect motor functional changes in young boys with Duchenne Muscular Dystrophy 51
Content validity and clinical meaningfulness of the HFMSE in spinal muscular atrophy 51
Clinical Variability in Spinal Muscular Atrophy Type III. 51
A critical review of patient and parent caregiver oriented tools to assess health-related quality of life, activity of daily living and caregiver burden in spinal muscular atrophy 51
Risdiplam-Treated Infants with Type 1 Spinal Muscular Atrophy versus Historical Controls 50
Duchenne muscular dystrophy: Preliminary experience with sacubitril-valsartan in patients with asymptomatic left ventricular dysfunction 50
Respiratory Trajectories in Type 2 and 3 Spinal Muscular Atrophy in the iSMAC Cohort Study 49
Categorizing natural history trajectories of ambulatory function measured by the 6-minute walk distance in patients with Duchenne muscular dystrophy 48
Development of an academic disease registry for spinal muscular atrophy 48
The Genetic Landscape of Dystrophin Mutations in Italy: A Nationwide Study 47
Estimating the impact of COVID-19 pandemic on services provided by Italian Neuromuscular Centers: an Italian Association of Myology survey of the acute phase 47
Totale 8.278
Salva come PNG Salva come JPEG
Categoria #
all - tutte 60.505
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 60.505
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020518 0 0 0 0 54 73 105 26 47 60 114 39
2020/2021502 44 43 15 38 47 43 73 12 62 30 90 5
2021/20221.137 80 37 21 110 80 38 23 192 68 67 208 213
2022/20233.068 302 382 200 459 193 393 217 271 382 48 142 79
2023/20242.604 109 459 99 176 101 401 351 102 52 129 269 356
2024/20251.252 124 99 399 243 387 0 0 0 0 0 0 0
Totale 10.878